1) What is the scope of ADR Monitoring?
Reporters are encouraged to report any suspicious adverse event, especially on:
- Newly registered drugs
- Reactions encountered with generic products which are not commonly associated with the equivalent market leader product
- Off-label indications
- Doses differing from the recommended doses
- Newly registered drugs
- Reactions encountered with generic products which are not commonly associated with the equivalent market leader product
- Off-label indications
- Doses differing from the recommended doses
2) What should not be reported?
Reactions to food products and unprocessed herbs should not be reported as these products are beyond the jurisdiction of the Drug Control Authority (DCA).
3) What to report?
If Healthcare Professionals feel that it is cumbersome to report trivial, common and well documented adverse reactions, they should report reactions which are serious, unexpected or unlabeled to the DCA.
4) How to report?
You can report any ADR cases using the Blue Form and send via one of these methods upon completion:
i. Mail the hardcopy to
Pusat Pasca Pendaftaran Produk & Kawalan Kosmetik
Agensi Regulatori Farmasi Negara (NPRA)
Lot 36, Jalan Universiti,
46200 Petaling Jaya, Selangor. OR
ii. Fax to 03-79567151 OR
iii. Email to This email address is being protected from spambots. You need JavaScript enabled to view it.
Please provide as much information as possible by filling up all the information as required in the form. The Blue Form is available in NPRA website http://npra.moh.gov.my
i. Mail the hardcopy to
Pusat Pasca Pendaftaran Produk & Kawalan Kosmetik
Agensi Regulatori Farmasi Negara (NPRA)
Lot 36, Jalan Universiti,
46200 Petaling Jaya, Selangor. OR
ii. Fax to 03-79567151 OR
iii. Email to This email address is being protected from spambots. You need JavaScript enabled to view it.
Please provide as much information as possible by filling up all the information as required in the form. The Blue Form is available in NPRA website http://npra.moh.gov.my
5) Basic principles of efficient reporting.
i. Report the event soon after it occurs.
ii. Report whilst the patient is still with you.
iii. Ask the patient particularly about other products taken.
iv. If any additional data is available later, send in a supplementary note.
v. In cases where a foetus or suckling infant sustains an ADR, information of both the parent and the child/fetus should be provided.
vi. Always write legibly.
vii. All reports must have minimum the following four data elements:
a) An identifiable patient
b) An identifiable reporter
c) A suspected drug
d) An adverse event
ii. Report whilst the patient is still with you.
iii. Ask the patient particularly about other products taken.
iv. If any additional data is available later, send in a supplementary note.
v. In cases where a foetus or suckling infant sustains an ADR, information of both the parent and the child/fetus should be provided.
vi. Always write legibly.
vii. All reports must have minimum the following four data elements:
a) An identifiable patient
b) An identifiable reporter
c) A suspected drug
d) An adverse event
6) Is there any guideline available for ADR reporting and monitoring?
The Malaysian Pharmacovigilance Guidelines is available in NPRA website.
